 |
|
Gene's Position in the Nucleus Can be Used to Distinguish Cancerous from Normal Breast Tissue
(Posted: 12/06/2009) - Researchers have identified several genes whose spatial position inside the cell nucleus is altered in invasive breast cancer when compared to normal breast tissue. The findings suggest that cancer cells may have disease-specific, three-dimensional gene arrangements and raise the possibility that such gene positioning patterns could be used as a new diagnostic strategy to distinguish cancer tissue from normal tissue.
News Note: NCI Awards Cancer Information Service Contact Center
(Posted: 12/03/2009) - The National Cancer Institute announced yesterday the selection of a single organization for a multiple year contract award to operate its Cancer Information Service (CIS) Contact Center. The program will be located at Fred Hutchinson Cancer Research Center in Seattle, Wash., and will serve the United States, Puerto Rico, the U.S. Virgin Islands, and the U.S.-associated Pacific Territories.
News Note: Addition of Cetuximab to Standard Chemotherapy in Early-Stage Colon Cancer Shows No Benefit in Phase 3 Clinical Trial
(Posted: 12/02/2009) - A Data Monitoring Committee (DMC) determined that in a phase 3 clinical trial for early-stage colon cancer, no group of patients benefited from the addition of the monoclonal antibody cetuximab (ErbituxTM) to a standard chemotherapy regimen known as FOLFOX. Detailed results from the study will be presented at a future scientific meeting.
NCI Statement on Breast Cancer Screening
(Posted: 11/16/2009) - NCI appreciates the U.S. Preventive Services Task Force's careful review and analysis of the evidence regarding breast cancer screening for women at average risk. The take-away message is that each woman needs to consider her individual benefits and risks and discuss them with her health care provider before making a decision on when to start screening mammography and how often to get
one.
 
Nicotine Patch - Nicotine Lozenge Combination Works Best For Smoking Cessation
(Posted: 11/02/2009) - In the largest study to date comparing smoking cessation therapies, the use of the nicotine lozenge in combination with the nicotine patch provided the greatest benefit for smokers trying to quit, resulting in over a two-fold better smoking cessation outcome 6 months after quitting compared to smokers who received placebo medication. The study also showed that this combination improved initial cessation and end of treatment quit rates compared to using just one therapy.
News Note: Strategy Sensitizes Tumors while Protecting Normal Tissues in Mice from Radiation Damage
(Posted: 10/21/2009) - Researchers at NCI and other institutes have developed a method that protects healthy tissues from the damaging effects of radiation treatment, while at the same time delaying tumor growth.
News Note: Comparative Effectiveness Grants in Genomic and Personalized Medicine Announced
(Posted: 10/21/2009) - As part of the American Recovery and Reinvestment Act of 2009, the National Cancer Institute, part of NIH, recently funded seven research and research infrastructure Grand Opportunities, or GO grants. The awards were for Comparative Effectiveness Research (CER) in genomic and personalized medicine (GPM).
Centralized Review Process Markedly Expedites Approval of Cancer Clinical Trials
(Posted: 10/19/2009) - A Central Institutional Review Board (CIRB) for cancer clinical trials that was created by the National Cancer Institute (NCI), part of the National Institutes of Health, in 2001 helps trials start more quickly (just over a month faster, on average) and thus expedite the time from concept to completion of crucial investigational research according to a new finding.
< Previous 1 2 3 Next >
 View Archive of News Releases
|
|
|
